Oracle Corporation (NYSE:ORCL) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.61% to $43.05. Oracle Corporation (ORCL) reported that fiscal 2017 Q3 results. Total Revenues were $9.2 billion, up 2% in U.S. dollars and up 3% in constant currency. Non-GAAP Total Revenues were $9.3 billion, up 3% in U.S. dollars and up 4% in constant currency.
Cloud software as a service (SaaS) and platform as a service (PaaS) revenues were $1.0 billion, up 73% in U.S. dollars and up 74% in constant currency. Non-GAAP SaaS and PaaS revenues were $1.1 billion, up 85% in U.S. dollars and up 86% in constant currency. Total Cloud Revenues, including infrastructure as a service (IaaS), were $1.2 billion, up 62% in U.S. dollars and up 63% in constant currency.
Total Cloud and On-Premise Software Revenues were $7.4 billion, up 4% in U.S. dollars and up 5% in constant currency. The share price of ORCL attracts active investors, as stock price of week volatility recorded 0.92%. The stock is going forward to its 52-week low with 14.88% and lagging behind from its 52-week high price with -0.49%.
Editas Medicine, Inc. (NASDAQ:EDIT) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -5.38% to close at $24.64 with the total traded volume of 1.25 Million shares. Editas Medicine, Inc. (EDIT), a leading genome editing company, recently reported that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 of shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine.
Editas Medicine intends to use the net proceeds of the offering to fund preclinical studies and clinical trials for our LCA10 program and our other programs to treat genetic and infectious diseases of the eye, preclinical studies of our programs to treat non-malignant hematologic diseases, preclinical studies in our collaboration with Juno Therapeutics, preclinical studies of other research programs, continued expansion of our platform technology, and for working capital and other general corporate purposes. The firm has institutional ownership of 75.10%, while insider ownership included 0.30%. Its price to sales ratio ended at 140.12. EDIT attains analyst recommendation of 2.20 with week’s performance of 12.31%.